淋巴瘤
伯基特淋巴瘤
医学
癌症研究
血液学
B细胞
肿瘤科
内科学
免疫学
抗体
作者
Sara Mato,Natalia Castrejón de Anta,Ariadna Colmenero,Lorenzo Carità,Julia Salmerón‐Villalobos,Joan E. Ramis-Zaldivar,Ferran Nadeu,Noelia García Barrio,Luojun Wang,Jaime Verdú‐Amorós,Mara Andrés,Núria Conde,Verónica Celis,Maria José Ortega,A. Galera,Itziar Astigarraga,Vanesa Pérez‐Alonso,Eduardo Quiroga,Aixiang Jiang,David W. Scott,Elı́as Campo,Olga Balagué,Itziar Salaverría
标识
DOI:10.1038/s41408-024-01153-0
摘要
Aggressive B-cell non-Hodgkin lymphomas (NHL) in children, adolescents, and young adults (CAYA) include Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and a subset of high-grade tumors with features intermediate between these entities whose genetic and molecular profiles have not been completely elucidated. In this study, we have characterized 37 aggressive B-NHL in CAYA, 33 with high-grade morphology, and 4 DLBCL with MYC rearrangement (MYC-R), using targeted next-generation sequencing and the aggressive lymphoma gene expression germinal center B-cell-like (GCB), activated B-cell-like (ABC), and dark zone signatures (DZsig). Twenty-two tumors had MYC-R without BCL2 breaks, and two MYC-non-R cases had BCL6 translocations. MYC-R cases, including DLBCL, carried BL-related mutations and copy number alterations. Conversely, MYC-non-R lymphomas had alterations in the B-cell receptor signaling/NF-κB pathway (71%). DZsig was expressed in 12/13 of MYC-R tumors but only in 2/10 of MYC-non-R GCB tumors (P < 0.001). The 3-year event-free survival (EFS) of the whole cohort was 79.6%. TP53 and KMT2C mutations conferred inferior outcome (3-year EFS P < 0.05). Overall, MYC-R lymphomas in CAYA have a molecular profile similar to BL regardless of their high-grade or DLBCL morphology, whereas MYC-non-R has more heterogeneous genetic alterations closer to that of DLBCL.
科研通智能强力驱动
Strongly Powered by AbleSci AI